Compare Amgen, Inc. (AMGN) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs LTC Properties Inc — how do they compare? Amgen, Inc. trades at $356.51 (market cap $196.12B), while LTC Properties Inc trades at $39.37 (market cap $1.99B). The key difference: Amgen, Inc. is far larger — about 98.6× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.87%). Which is the better fit depends on your goals.
| AMGN | LTC | |
|---|---|---|
Market Cap | $196.12B | $1.99B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $40.36 |
52-Week Low | $271.18 | $33.98 |
Enterprise Value | $241.41B | $2.84B |
Dividend Yield | 2.77% | 5.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
LTC Properties trades at $38.86, down 0.72% on the day, with a bullish technical signal from moving averages and a neutral RSI. The REIT shows strong profitability with a 39.09% net income margin and a P/E of 15.24. Recent acquisitions, including a $73 million SHOP portfolio expansion (Business Wire, 2026-07-08), highlight growth initiatives, while consistent monthly dividends of $0.19 provide income appeal.
The outlook is mixed: analyst consensus leans Hold (59.09%) amid recent earnings misses, but bullish technicals and strategic shifts to seniors housing offer upside. Risks include execution on SHOP transitions and debt levels, with net cash flow turning negative in 2026. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
